Novakand Pharma Inherits Catastrophic Regulatory Risk in SVF Vaccines RTO
Novakand Pharma AB's reverse takeover of SVF Vaccines exposes the Nasdaq First North Premier-listed entity to pharmaceutical regulatory risk rated catastrophic severity with 70% confidence. The combined entity inherits SVF Vaccines' clinical trial pipeline and manufacturing compliance obligations under EMA and FDA oversight.
ViaNews Editorial Team (Markets)•